Corbyn Investment Management Inc. MD Purchases Shares of 3,460 Hologic, Inc. (NASDAQ:HOLX)

Corbyn Investment Management Inc. MD purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, Holdings Channel.com reports. The fund purchased 3,460 shares of the medical equipment provider’s stock, valued at approximately $247,000.

Several other hedge funds have also recently modified their holdings of the stock. CWM LLC raised its stake in Hologic by 5.8% in the 3rd quarter. CWM LLC now owns 6,972 shares of the medical equipment provider’s stock worth $484,000 after acquiring an additional 384 shares during the last quarter. AE Wealth Management LLC raised its stake in shares of Hologic by 23.7% in the third quarter. AE Wealth Management LLC now owns 5,504 shares of the medical equipment provider’s stock worth $382,000 after purchasing an additional 1,056 shares during the last quarter. HB Wealth Management LLC lifted its holdings in shares of Hologic by 18.1% during the third quarter. HB Wealth Management LLC now owns 5,774 shares of the medical equipment provider’s stock worth $401,000 after purchasing an additional 884 shares during the period. SG Americas Securities LLC boosted its position in Hologic by 49.5% in the third quarter. SG Americas Securities LLC now owns 47,420 shares of the medical equipment provider’s stock valued at $3,291,000 after buying an additional 15,706 shares during the last quarter. Finally, LaFleur & Godfrey LLC increased its holdings in Hologic by 3.8% in the 3rd quarter. LaFleur & Godfrey LLC now owns 138,925 shares of the medical equipment provider’s stock worth $9,641,000 after buying an additional 5,028 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX stock traded up $0.79 during trading hours on Friday, hitting $76.50. 349,790 shares of the company’s stock were exchanged, compared to its average volume of 1,761,588. The firm has a market cap of $17.96 billion, a P/E ratio of 35.88, a P/E/G ratio of 2.60 and a beta of 1.00. The firm has a 50 day moving average of $75.98 and a two-hundred day moving average of $72.74. Hologic, Inc. has a fifty-two week low of $64.02 and a fifty-two week high of $87.88. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. During the same quarter in the previous year, the company posted $1.07 EPS. The company’s revenue was down 5.7% compared to the same quarter last year. Sell-side analysts forecast that Hologic, Inc. will post 4.01 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on HOLX shares. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research note on Friday, March 8th. Evercore ISI upped their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their target price for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Finally, Raymond James lifted their price target on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $87.00.

Insider Activity

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at approximately $119,802.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock valued at $2,473,443 in the last 90 days. Company insiders own 1.75% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.